评估依巴斯汀的心脏安全性。结语。 - Suppr

Suppr

超能文献

Assessing the cardiac safety of ebastine. Epilogue.

作者信息

Roberts D J

机构信息

Scientific and Regulatory Affairs, Almirall Prodesfarma, Barcelona, Spain.

出版信息

Drug Saf. 1999;21 Suppl 1:89-92. doi: 10.2165/00002018-199921001-00011.

DOI:10.2165/00002018-199921001-00011

PMID:10597871

Abstract

摘要

相似文献

Assessing the cardiac safety of ebastine. Epilogue.

Drug Saf. 1999;21 Suppl 1:89-92. doi: 10.2165/00002018-199921001-00011.

Of oocytes and runny noses.

Circulation. 1996 Aug 15;94(4):607-9. doi: 10.1161/01.cir.94.4.607.

Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.

J Med Chem. 2003 May 22;46(11):2017-22. doi: 10.1021/jm0205651.

[Etiological mechanism of long QT syndrome and the effects of macrolides].

Jpn J Antibiot. 2001 Feb;54 Suppl A:118-22.

Evaluation of the cardiac safety of second-generation antihistamines.

Allergy. 2000;55 Suppl 60:22-30. doi: 10.1034/j.1398-9995.2000.00004.x.

Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.

Eur J Pharmacol. 2003 Apr 11;466(1-2):137-46. doi: 10.1016/s0014-2999(03)01559-0.

Assessing the cardiac safety of ebastine. Prologue.

Drug Saf. 1999;21 Suppl 1:1-3. doi: 10.2165/00002018-199921001-00001.

Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole.

J Cardiovasc Electrophysiol. 1999 Jun;10(6):836-43. doi: 10.1111/j.1540-8167.1999.tb00264.x.

Cardiovascular profile of loratadine.

Clin Exp Allergy. 1999 Jul;29 Suppl 3:197-9. doi: 10.1046/j.1365-2222.1999.0290s3197.x.

H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects.

Clin Exp Allergy. 2002 Apr;32(4):489-98. doi: 10.1046/j.0954-7894.2002.01314.x.

本文引用的文献

Cardiac effects of ebastine and other antihistamines in humans.

Drug Saf. 1999;21 Suppl 1:69-80; discussion 81-7. doi: 10.2165/00002018-199921001-00009.

Blockade of cardiac potassium and other channels by antihistamines.

Drug Saf. 1999;21 Suppl 1:11-8; discussion 81-7. doi: 10.2165/00002018-199921001-00003.

Cardiotoxicity of second-generation antihistamines.

Drugs. 1999 Jun;57(6):1033-4. doi: 10.2165/00003495-199957060-00018.

Comparative tolerability of second generation antihistamines.

Drug Saf. 1999 May;20(5):385-401. doi: 10.2165/00002018-199920050-00001.

Variations among non-sedating antihistamines: are there real differences?

Eur J Clin Pharmacol. 1999 Apr;55(2):85-93. doi: 10.1007/s002280050600.

Second-generation antihistamines: a comparative review.

Drugs. 1999 Jan;57(1):31-47. doi: 10.2165/00003495-199957010-00004.

Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.

Mol Pharmacol. 1998 Jul;54(1):113-21. doi: 10.1124/mol.54.1.113.

Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig.

Arzneimittelforschung. 1996 Aug;46(8):832-3.

Suppression of mammalian K+ channel family by ebastine.

J Pharmacol Exp Ther. 1997 Apr;281(1):233-44.

The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity.

Br J Pharmacol. 1996 Sep;119(2):187-8. doi: 10.1111/j.1476-5381.1996.tb15968.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验